Sarepta Therapeutics, Inc. SRPT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $330.96M+217% | -$282.85M-57.2% | -$179.95M— | —— | -$447.51M-381% | ||
| $10.59M+102% | $5.25M-71.5% | $18.45M+70.2% | $10.84M+8.6% | $9.98M-4.6% | ||
| $29.4M-2.1% | $30.02M+101% | $14.93M-59.7% | $37.03M-10.6% | $41.43M-16.6% | ||
| -$3.42M— | $0+100% | -$131.56M+0.4% | -$132.08M-330% | $57.38M-65.7% | ||
| $69.76M— | $0-100% | $83.02M+40.3% | $59.19M-66.6% | $177.36M+9.7% | ||
| -$210.47M— | —— | —— | —— | -$58.34M— | ||
| -$60.03M— | —— | —— | —— | $31.65M— | ||
| $14.55M— | —— | $62.81M+183% | $22.19M+47.3% | $15.07M— | ||
| $1.29M+149% | -$2.62M-130% | -$1.14M+60.3% | -$2.87M-554% | -$438K— | ||
| -$274.92M-757% | $41.86M-53.5% | $90.02M+252% | $25.57M+130% | -$85.4M— | ||
| -$1.71M— | —— | —— | $36.72M+140% | -$90.73M— | ||
| -$202.68M— | —— | -$14.59M— | —— | -$583.44M— | ||
| $2.08M-42.0% | $3.59M-84.3% | $22.93M-27.9% | $31.8M-27.2% | $43.65M+14.6% | ||
| $170.2M— | —— | —— | —— | $44.66M-72.6% | ||
| $38.89M— | $0-100% | $64.71M-5.7% | $68.63M+68.4% | $40.76M— | ||
| $1M+625% | $138K-97.4% | $5.31M+2,726% | $188K-91.6% | $2.24M— | ||
| -$134.39M-240% | $96.21M— | —— | —— | -$291.18M-138% | ||
| $250M— | —— | —— | —— | $0— | ||
| $250M+613% | $35.09M— | —— | —— | $0— | ||
| $241K— | $0-100% | $2.82M+87.9% | $1.5M-90.4% | $15.68M— | ||
| $241K+101% | -$39.21M+66.7% | -$117.79M-395% | -$23.82M-291% | $12.47M-74.5% | ||
| -$336.83M— | —— | —— | —— | -$862.14M-195% | ||
| $23.42M+2,363% | $951K-86.0% | $6.77M— | $0-100% | $7.19M+946% | ||
| $1.73M-89.5% | $16.38M+1,317% | $1.16M-94.0% | $19.26M+2,206% | $835K-92.4% | ||
| -$530K-39.5% | -$380K+66.5% | -$1.13M+39.3% | -$1.87M+2.4% | -$1.91M+71.9% | ||
| -$1.71M— | —— | —— | $36.72M+140% | -$90.73M— | ||
| -$3.44M— | —— | —— | —— | $8.98M— | ||
| -$274.92M-757% | $41.86M-53.5% | $90.02M+252% | $25.57M+130% | -$85.4M— | ||
| -$43.49M-270% | -$11.77M— | —— | —— | -$71.14M— | ||
| $14.55M— | —— | $62.81M+183% | $22.19M+47.3% | $15.07M— | ||
| —— | $41.31M0.0% | $41.31M0.0% | $41.31M0.0% | $41.31M— | ||
| $9.61M— | —— | —— | —— | $1.25M+4.2% | ||
| $1.29M+149% | -$2.62M-130% | -$1.14M+60.3% | -$2.87M-554% | -$438K— | ||
| $3.11M+18.5% | $2.63M-22.1% | $3.37M-16.2% | $4.02M+2.2% | $3.93M+1.4% | ||
| $0— | —— | —— | -$4.43M+98.2% | -$241.39M— | ||
| $1M+625% | $138K-97.4% | $5.31M+2,726% | $188K-91.6% | $2.24M— | ||
| $38.89M-61.1% | $99.94M+15.5% | $86.55M+26.1% | $68.63M+68.4% | $40.76M-95.8% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $0-100% | $48K-92.1% | $608K+100% | $304K-90.5% | $3.21M— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| —— | $11.85M0.0% | $11.85M0.0% | $11.85M0.0% | $11.85M— | ||
| —— | $5.27M0.0% | $5.27M0.0% | $5.27M0.0% | $5.27M— | ||
| $5.95M— | —— | —— | —— | $29.23M+228% | ||
| —— | $3.07M0.0% | $3.07M0.0% | $3.07M0.0% | $3.07M— | ||
| $0— | —— | —— | —— | $5.23M-65.1% | ||
| $1.73M-89.5% | $16.38M+1,317% | $1.16M-94.0% | $19.26M+2,206% | $835K-92.4% | ||
| -$204.76M— | —— | -$37.52M— | —— | -$627.09M— | ||
| -$204.76M— | —— | -$37.52M— | —— | -$627.09M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Sarepta Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.